Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Sanofi-aventis Aims at 31 Submissions by the End of 2010
October 22, 2007
-
ARCHIVE DIA Workshop Focuses on Collaborative Clinical Trials in Asia
October 22, 2007
-
ARCHIVE R&D NEWS IN BRIEF
October 22, 2007
-
ARCHIVE SymBio Begins PI Study of SyB-0702 in US
October 22, 2007
-
ARCHIVE VITAL-NET, KSK Enter into Comprehensive Business Alliance
October 15, 2007
-
ARCHIVE Physician-Initiated Trials Led by JMACCT Generating Results
October 15, 2007
-
ARCHIVE Council Recommends Improvements of Drug Trade Practices
October 15, 2007
-
ARCHIVE Guideline Issued on Multinational Cooperative Clinical Studies
October 15, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
October 15, 2007
-
ARCHIVE Number of Documents Necessary for Clinical Trials Halved
October 15, 2007
-
ARCHIVE TOPICS/2007 JCA-Mauvernay Award Granted to 2 Japanese Scientists
October 15, 2007
-
ARCHIVE Korosho Proposes Higher Premiums for Pediatric and Orphan Drugs: Chuikyo
October 15, 2007
-
ARCHIVE R&D NEWS IN BRIEF
October 15, 2007
-
ARCHIVE Given Imaging's Capsule Endoscope to Be Reimbursed at \77,200
October 15, 2007
-
ARCHIVE World's First Recombinant Serum Albumin Recommended for Approval
October 15, 2007
-
ARCHIVE Takara Bio Licenses LA-PCR Technology to Kapa Biosystems
October 15, 2007
-
ARCHIVE Genzyme's Elaprase Receives Ultra-early Approval
October 15, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
October 15, 2007
-
ARCHIVE Approval of Concerta for ADHD Withheld
October 15, 2007
-
ARCHIVE Inhibition of Both Absorption and Production of LDL-C Important: Schering-Plough
October 15, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…